| Filed On | Filing |
|---|---|
| 07 Jan 2021 |
8-K/A: Regulation FD Disclosure
ANGIODYNAMICS Second Quarter 2021 Earnings PresentationJanuary 7, 2021 1 |
| 08 Apr 2020 |
8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure
On April 7, 2020, AngioDynamics, Inc. (“AngioDynamics”) issued a press release announcing financial results for the fiscal third quarter ended February 29, 2020. A copy of the press release is furnished herewith as Exhibit 99.1. |
| 04 Aug 2017 |
8-K/A: Results of Operations and Financial Condition
(1) Includes costs related to mergers and acquisition activities, integrations, restructurings, asset impairments and write-offs, litigation, and other items. |
| 08 Sep 2016 |
8-K/A: Departure/Election of Directors or Officers; Compensation
As previously announced in the Original Report, the Company and Mark Stephens, Senior Vice President, Administration, of the Company, agreed that Mr. Stephens would leave the Company. Mr. Stephens’ final day of employment with the Compan... |
| 03 Aug 2012 |
8-K/A: Financial Statements and Exhibits
On May 22, 2012 (the “Closing Date”), AngioDynamics, Inc. (“AngioDynamics”) completed the acquisition of privately-held Navilyst Medical, Inc. (“Navilyst”). The following unaudited pro forma condensed combined financial statements are de... |
| 25 Jan 2007 |
8-K/A: Other Events
On January 25, 2007, AngioDynamics, Inc. (the "Company") and RITA Medical Systems, Inc. ("RITA") disclosed that pursuant to the terms of their previously announced Agreement and Plan of Merger and based on the average closing price of th... |
Loading...